

Registered number: 13057708

G&L SCIENTIFIC HOLDINGS LIMITED

**ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**



G&L SCIENTIFIC HOLDINGS LIMITED
--

COMPANY INFORMATION

Directors	Peter William Griffin (appointed 2 December 2020) Stephen Loughrey (appointed 2 December 2020)
------------------	---

Registered number	13057708
--------------------------	----------

Registered office	The Old Barrel Store Brewery Courtyard Draymans Lane Marlow SL7 2FF
--------------------------	---

Independent auditors	MHA Macintyre Hudson Building 4 Foundation Park Roxborough Way Maidenhead Berkshire SL6 3UD
-----------------------------	---

G&L SCIENTIFIC HOLDINGS LIMITED

CONTENTS

	Page
Group strategic report	1 - 2
Directors' report	3 - 4
Independent auditors' report	5 - 8
Consolidated statement of comprehensive income	9
Consolidated balance sheet	10
Company balance sheet	11
Consolidated statement of changes in equity	12
Company statement of changes in equity	13
Consolidated Statement of cash flows	14
Consolidated analysis of net debt	15
Notes to the financial statements	16 - 31

G&L SCIENTIFIC HOLDINGS LIMITED

GROUP STRATEGIC REPORT FOR THE PERIOD ENDED 31 DECEMBER 2021

Introduction

The directors present their strategic report for the group.

Strategy and business model

G&L Scientific Holdings Limited is a provider of regulatory affairs and quality assurance consultancy services to the global pharmaceutical sector. The market serviced within the pharmaceutical sector continues to be attractive and buoyant, despite significant recent economic events such as Covid-19 pandemic and Brexit. The strategy of the business is as follows:

- Develop existing client relationships and repeat business opportunities;
- Seek new client relationships through business development initiative.

Business review

Turnover in 2021 has increased to £17.2m in 2021 through organic growth and improved cost of sales has resulted in a positive change in gross profit. Planned investments in management and back office systems, designed to facilitate future growth, have resulted in administrative cost increases and an associated decrease in operating profit margin.

Overall, the business continues to grow and is strengthened through investments financed through ongoing activities, as opposed to leverage through long term debt. Net Assets have increased by £720k in 2021, as the group reduced its long term debt by £909k by the end of the period.

Principal risks and uncertainties

The directors have identified the following principal risks and uncertainties affecting the company:

Market risk: Global outsourcing for regulatory and quality assurance services in the pharmaceutical sector continues to experience strong growth and, therefore, the company is relatively well positioned and insulated from global economic events. There has been no material economic impact from Covid-19 and/or Brexit to the group which services its broad client base in multiple countries. Global economic conditions and uncertainty continues to be monitored, noting a prospect of increasing inflation in the future of most interest.

The group is affected by the relative availability and market price of technical expertise, and the group manages its exposure through brand marketing for attracting talent and human resource management practices to support its employee value proposition.

Legislative and regulatory risk (4) : The UK Government has implemented off-payroll working rules (IR35) which has required strong expertise in the area to manage temporary resources. This is considered an additional regulatory burden rather than a risk to future business activity.

Sound financial practices are in place to manage risks associated with cash flow in the growing business.

Actions of competitors: Consolidation in the market place has reduced the numbers of competitors although threat of competition has strengthened at the same time. Shortage of talent in the industry has increased competition for resources. The directors remain confident in a strong value proposition for staff and the quality of relationships built over an extended period of time to retain and attract talent.

G&L SCIENTIFIC HOLDINGS LIMITED

**GROUP STRATEGIC REPORT (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2021**

Financial key performance indicators

The group monitors its performance using a number of operational and financial measures. Apart from those variables identified above in the business review, the directors are of the opinion that no further inclusion of financial and non-financial key performance indicators is necessary for an understanding of the development, performance or position of the group's business.

This report was approved by the board on 27 September 2022 and signed on its behalf.



.....
Peter William Griffin
Director

G&L SCIENTIFIC HOLDINGS LIMITED

DIRECTORS' REPORT FOR THE PERIOD ENDED 31 DECEMBER 2021

The directors present their report and the financial statements for the period ended 31 December 2021.

Directors' responsibilities statement

The directors are responsible for preparing the Group strategic report, the Directors' report and the consolidated financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and the Group and of the profit or loss of the Group for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the Group's financial statements and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and the Group and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Results and dividends

The group profit for the period, after taxation, amounted to £585,635 (2020 - £1,514,182).

The directors have not recommended a dividend this year.

Directors

The directors who served during the period were:

Peter William Griffin (appointed 2 December 2020)
Stephen Loughrey (appointed 2 December 2020)

Future developments

The company anticipates strong trading conditions with an anticipated increase in demand for our services. We are targeting income growth in all regions in which we operate.

G&L SCIENTIFIC HOLDINGS LIMITED

**DIRECTORS' REPORT (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2021**

Disclosure of information to auditors

Each of the persons who are directors at the time when this Directors' report is approved has confirmed that:

- so far as the director is aware, there is no relevant audit information of which the Company and the Group's auditors are unaware, and
- the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company and the Group's auditors are aware of that information.

Post balance sheet events

There have been no significant events affecting the Group since the year end.

Auditors

The auditors, MHA Macintyre Hudson, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report was approved by the board on 27 September 2022 and signed on its behalf.



Peter William Griffin
Director

G&L SCIENTIFIC HOLDINGS LIMITED

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF G&L SCIENTIFIC HOLDINGS LIMITED

Opinion

We have audited the financial statements of G&L Scientific Holdings Limited (the 'parent Company') and its subsidiaries (the 'Group') for the period ended 31 December 2021, which comprise the Group Statement of comprehensive income, the Group and Company Balance sheets, the Group Statement of cash flows, the Group and Company Statement of changes in equity and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent Company's affairs as at 31 December 2021 and of the Group's profit for the period then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

G&L SCIENTIFIC HOLDINGS LIMITED

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF G&L SCIENTIFIC HOLDINGS LIMITED
(CONTINUED)**

Other information

The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' report thereon. The directors are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Group strategic report and the Directors' report for the financial period for which the financial statements are prepared is consistent with the financial statements; and
- the Group strategic report and the Directors' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Group and the parent Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group strategic report or the Directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent Company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent Company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

G&L SCIENTIFIC HOLDINGS LIMITED

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF G&L SCIENTIFIC HOLDINGS LIMITED (CONTINUED)

Responsibilities of directors

As explained more fully in the Directors' responsibilities statement set out on page 3, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Group's and the parent Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or the parent Company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Group financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- Enquiry of management and those charged with governance around actual and potential litigation and claims;
- Performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias;
- Reviewing minutes of meetings of those charged with governance;
- Substantive testing to ensure accuracy for key financial statement areas;
- Analytical procedures to highlight any unexpected discrepancies;
- Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.

G&L SCIENTIFIC HOLDINGS LIMITED
--


**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF G&L SCIENTIFIC HOLDINGS LIMITED
(CONTINUED)**

Other matters

The financial statements of G&L Scientific Holdings Ltd for the year ended 31 December 2020 were unaudited. As noted in the accounting policies, merger accounting has been used as permitted for group reconstructions.

Use of our report

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



BIANCA SILVA BA ACA DChA (Senior statutory auditor)

for and on behalf of

MHA Macintyre Hudson

Statutory Auditor

Maidenhead, United Kingdom

30 September 2022

G&L SCIENTIFIC HOLDINGS LIMITED

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 31 DECEMBER 2021**

	Note	2021 £	2020 £
Turnover	4	17,252,130	15,680,199
Cost of sales		(10,213,420)	(9,322,601)
Gross profit		7,038,710	6,357,598
Administrative expenses		(6,072,385)	(4,329,923)
Operating profit	5	966,325	2,027,675
Interest payable and similar expenses	9	(102,270)	(204,601)
Profit before tax		864,055	1,823,074
Tax on profit	10	(278,420)	(308,892)
Profit for the financial year		585,635	1,514,182
Profit for the year attributable to:			
Owners of the parent company		585,635	1,514,182
		585,635	1,514,182

There were no recognised gains and losses for 2021 or 2020 other than those included in the consolidated statement of comprehensive income.

The notes on pages 16 to 31 form part of these financial statements.

G&L SCIENTIFIC HOLDINGS LIMITED
REGISTERED NUMBER: 13057708

CONSOLIDATED BALANCE SHEET
AS AT 31 DECEMBER 2021

	Note	2021 £	2020 £
Fixed assets			
Tangible assets	12	232,555	159,431
		<u>232,555</u>	<u>159,431</u>
Current assets			
Debtors: amounts falling due within one year	14	3,434,216	3,300,616
Cash at bank and in hand	15	705,999	869,048
		<u>4,140,215</u>	<u>4,169,664</u>
Creditors: amounts falling due within one year	16	(3,046,523)	(2,814,424)
Net current assets		<u>1,093,692</u>	<u>1,355,240</u>
Total assets less current liabilities		<u>1,326,247</u>	<u>1,514,671</u>
Creditors: amounts falling due after more than one year	17	(600,000)	(1,508,746)
Net assets		<u><u>726,247</u></u>	<u><u>5,925</u></u>
Capital and reserves			
Called up share capital	18	20,000	-
Foreign exchange reserve	19	42,781	(71,979)
Merger reserve	19	(55,841)	(55,841)
Profit and loss account	19	719,307	133,745
		<u><u>726,247</u></u>	<u><u>5,925</u></u>

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 27 September 2022.



.....
Peter William Griffin
 Director

The notes on pages 16 to 31 form part of these financial statements.

G&L SCIENTIFIC HOLDINGS LIMITED
REGISTERED NUMBER: 13057708

COMPANY BALANCE SHEET
AS AT 31 DECEMBER 2021

	Note	2021 £	2020 £
Fixed assets			
Investments	13	15,250,290	-
		<u>15,250,290</u>	<u>-</u>
Total assets less current liabilities		15,250,290	-
Net assets		<u>15,250,290</u>	<u>-</u>
Capital and reserves			
Called up share capital	18	20,000	-
Share premium account	19	15,230,290	-
		<u>15,250,290</u>	<u>-</u>

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 27 September 2022.



Peter William Griffin
Director

The notes on pages 16 to 31 form part of these financial statements.

G&L SCIENTIFIC HOLDINGS LIMITED

**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 DECEMBER 2021**

	Called up share capital	Foreign exchange reserve	Merger reserve	Profit and loss account	Total equity
	£	£	£	£	£
At 1 January 2021	-	-	(55,841)	133,672	77,831
Profit for the period	-	-	-	585,635	585,635
Currency translation differences	-	42,781	-	-	42,781
Total comprehensive income for the period	-	42,781	-	585,635	628,416
Shares issued during the period	20,000	-	-	-	20,000
Total transactions with owners	20,000	-	-	-	20,000
At 31 December 2021	20,000	42,781	(55,841)	719,307	726,247

The notes on pages 16 to 31 form part of these financial statements.

G&L SCIENTIFIC HOLDINGS LIMITED

**COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 DECEMBER 2021**

	Called up share capital £	Share premium account £	Total equity £
Other comprehensive income for the period	-	-	-
Total comprehensive income for the period	-	-	-
Contributions by and distributions to owners			
Shares issued during the period	20,000	15,230,290	15,250,290
Total transactions with owners	20,000	15,230,290	15,250,290
At 31 December 2021	20,000	15,230,290	15,250,290

The notes on pages 16 to 31 form part of these financial statements.

G&L SCIENTIFIC HOLDINGS LIMITED

**CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

	2021 £	2020 £
Cash flows from operating activities		
Profit for the financial period	585,635	1,514,182
Adjustments for:		
Depreciation of tangible assets	86,946	70,767
Interest paid	102,270	204,601
Taxation charge	278,420	308,892
(Increase) in debtors	(132,068)	(1,111,845)
(Decrease)/increase in creditors	(33,579)	794,949
Corporation tax (paid)	(314,564)	(86,811)
Foreign exchange	114,760	2,896
Net cash generated from operating activities	687,820	1,697,631
Cash flows from investing activities		
Purchase of tangible fixed assets	(96,714)	(86,842)
Fixed assets on acquisition of subsidiaries	(62,269)	-
Net cash from investing activities	(158,983)	(86,842)
Cash flows from financing activities		
Issue of ordinary shares	20,000	-
New secured loans	629,381	-
Repayment of loans	(592,315)	-
Repayment of other loans	(600,687)	(1,328,341)
Interest paid	(148,265)	-
Net cash used in financing activities	(691,886)	(1,328,341)
Net (decrease)/increase in cash and cash equivalents	(163,049)	282,448
Cash and cash equivalents at beginning of period	869,048	586,600
Cash and cash equivalents at the end of period	705,999	869,048
Cash and cash equivalents at the end of period comprise:		
Cash at bank and in hand	705,999	869,048
	705,999	869,048

The notes on pages 16 to 31 form part of these financial statements.

G&L SCIENTIFIC HOLDINGS LIMITED

**CONSOLIDATED ANALYSIS OF NET DEBT
FOR THE PERIOD ENDED 31 DECEMBER 2021**

	At 1 January 2021 £	Cash flows £	Other non- cash changes £	At 31 December 2021 £
Cash at bank and in hand	869,048	(163,049)	-	705,999
Debt due after 1 year	(1,508,746)	494,295	414,451	(600,000)
Debt due within 1 year	-	(37,066)	(414,451)	(451,517)
	<u>(639,698)</u>	<u>294,180</u>	<u>-</u>	<u>(345,518)</u>

The notes on pages 16 to 31 form part of these financial statements.

G&L SCIENTIFIC HOLDINGS LIMITED
--

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

1. General information

G&L Scientific Holdings Ltd is a private company limited by shares, incorporated in England registration number 130577708 whose registered office is at The Old Barrel Store, Brewery Courtyard, Draymans Lane, Marlow, SL7 2FF.

The principal activities of the Group are human resource provision and management of human resource functions for Regulatory Affairs and Quality Assurance services to clients.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires Group management to exercise judgment in applying the Group's accounting policies (see note 3).

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of comprehensive income in these financial statements.

The following principal accounting policies have been applied:

G&L SCIENTIFIC HOLDINGS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

2. Accounting policies (continued)

2.2 Basis of consolidation

The consolidated financial statements present the results of the Company and its own subsidiaries ("the Group") as if they form a single entity. Intercompany transactions and balances between group companies are therefore eliminated in full.

In accordance with the transitional exemption available in FRS 102, the group has chosen not to retrospectively apply the standard to business combinations that occurred before the date of transition to FRS 102

The consolidated financial statements incorporate the results of business combinations and group reconstructions.

In the Balance Sheet, an acquiree's identifiable assets, liabilities and contingent liabilities are initially recognized at their fair values at the acquisition date. The results of acquired operations are included in the Consolidated Statement of Comprehensive Income from the date on which control is obtained.

Merger accounting is permitted under FRS102 where it related to group reconstructions.

Where merger accounting applies, the results and cash flows of all the combining entities are brought into the financial statements of the combined entity as if it had always existed and adjusted so as to achieve uniformity of accounting policies. Comparative information includes the total comprehensive income for all the combining entities for the previous reporting period and their statement of financial position for the previous reporting date, adjusted as necessary to achieve uniformity of accounting policies.

The Company was incorporated on 2 December 2020 and effected the group reconstruction on 1 January 2021. The Company's subsidiaries produce accounts for the year ended 31 December. Since the Company was brought into existence only to effect the group reconstruction, the Consolidated Statement of Comprehensive income includes the results of the subsidiary companies for the year ended 31 December 2021 and the comparative period is the year ended 31 December 2020.

The balance sheet date for the Group in the current and previous period is 31 December 2021 and 31 December 2020 respectively.

In the opinion of the Directors this is the most appropriate presentation of the Group results for the users for these financial statements.

Therefore, the Group continues to recognise a merger reserve which arose on a past business combination that was accounted for as a merger in accordance with UK GAAP as applied at that time.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

2. Accounting policies (continued)

2.3 Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

2.4 Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

- the amount of revenue can be measured reliably;
- it is probable that the Group will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

2.5 Operating leases: the Group as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

G&L SCIENTIFIC HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.6 Pensions

Defined contribution pension plan

The Group operates a number of defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Group pays fixed contributions into a separate entity. Once the contributions have been paid the Group has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Group in independently administered funds.

2.7 Current and deferred taxation

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company and the Group operate and generate income.

2.8 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

The Group adds to the carrying amount of an item of fixed assets the cost of replacing part of such an item when that cost is incurred, if the replacement part is expected to provide incremental future benefits to the Group. The carrying amount of the replaced part is derecognised. Repairs and maintenance are charged to profit or loss during the period in which they are incurred.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment	- 33% on cost
Computer equipment	- 33% on cost
Leasehold property improvements	- 20% straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

G&L SCIENTIFIC HOLDINGS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

2. Accounting policies (continued)

2.9 Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

2.10 Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.11 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

In the Consolidated statement of cash flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and form an integral part of the Group's cash management.

2.12 Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.13 Financial instruments

The Group only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

3. Judgments in applying accounting policies and key sources of estimation uncertainty

Management has made judgements as to the extent of any need for provisions for repairs in respect of leased property wear and tear, or reinstatement costs. Management has considered the nature of the work carried out by the company on its leased premises and estimated the extent to which repairs or reinstatement will be necessary at the end of the lease.

As repairs or reinstatement costs are likely to arise on expiry of the lease, a suitable provision for repairs or reinstatement has been recognised in the accounts, as detailed in note 15. The suitability of this provision will be reviewed by management annually and any events that may have a material impact will be reflected in the provision.

There are no other key sources of estimation uncertainty.

G&L SCIENTIFIC HOLDINGS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

4. Turnover

Analysis of turnover by country of destination:

	2021 £	2020 £
United Kingdom	3,345,350	3,996,333
Rest of the world	13,906,780	11,683,866
	<u>17,252,130</u>	<u>15,680,199</u>

5. Operating profit

The operating profit is stated after charging:

	2021 £	2020 £
Depreciation of tangible fixed assets	86,946	70,767
Exchange differences	176,498	(201)
Other operating lease rentals	317,928	274,435
	<u>571,372</u>	<u>345,001</u>

6. Auditors' remuneration

	2021 £	2020 £
Fees payable to the Group's auditor and its associates for the audit of the Group's annual financial statements	25,000	-
Fees payable to the Group's auditor and its associates in respect of:		
Taxation compliance services	14,640	-
All other services	39,445	28,981
	<u>54,085</u>	<u>28,981</u>

G&L SCIENTIFIC HOLDINGS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

7. Employees

Staff costs, including directors' remuneration, were as follows:

	Group 2021 £	Group 2020 £	Company 2021 £	Company 2020 £
Wages and salaries	9,837,531	6,554,413	-	-
Social security costs	353,467	289,905	-	-
Cost of defined contribution scheme	365,517	279,414	-	-
	<u>10,556,515</u>	<u>7,123,732</u>	<u>-</u>	<u>-</u>

The average monthly number of employees, including the directors, during the period was as follows:

	2021 No.	2020 No.
Employees	<u>153</u>	<u>147</u>

8. Directors' remuneration

	2021 £	2020 £
Directors' emoluments	566,535	18,731
	<u>566,535</u>	<u>18,731</u>

The highest paid director received remuneration of £566,535 (2020 - £18,731).

The value of the Group's contributions paid to a defined contribution pension scheme in respect of the highest paid director amounted to £NIL (2020 - £NIL).

The value of the Group's contributions paid to a defined benefit pension scheme in respect of the highest paid director amounted to £NIL (2020 - £NIL).

The total accrued pension provision of the highest paid director at 31 December 2021 amounted to £NIL (2020 - £NIL).

The amount of the accrued lump sum in respect of the highest paid director at 31 December 2021 amounted to £NIL (2020 - £NIL).

G&L SCIENTIFIC HOLDINGS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

9. Interest payable and similar expenses

	2021 £	2020 £
Other loan interest payable	102,270	204,601
	<u>102,270</u>	<u>204,601</u>

10. Taxation

	2021 £
Corporation tax	
Current tax for the year	280,004
	<u>280,004</u>
Total current tax	<u>280,004</u>
Deferred tax	
Origination and reversal of timing differences	(1,584)
Total deferred tax	<u>(1,584)</u>
Taxation on profit on ordinary activities	<u>278,420</u>

G&L SCIENTIFIC HOLDINGS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

10. Taxation (continued)

Factors affecting tax charge for the period/year

The tax assessed for the period/year is higher than (2020 - *higher than*) the standard rate of corporation tax in the UK of 19% (2020 - 19%). The differences are explained below:

	2021 £
Profit on ordinary activities before tax	864,055
Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 19% (2020 - 19%)	164,170
Effects of:	
Expenses not deductible for tax purposes, other than goodwill amortisation and impairment	4,160
Capital allowances for period/year in excess of depreciation	(6,745)
Short-term timing difference leading to an increase in taxation	19,177
Other timing differences leading to an increase (decrease) in taxation	768
Unrelieved loss on foreign subsidiaries	27,893
Variation in group tax rates leading to an increase in the tax charge	68,997
Total tax charge for the period/year	278,420

Factors that may affect future tax charges

From 1 April 2023 the corporation tax main rate will rise to 25% from 19% for profits exceeding £250,000. A small profits rate of 19% will be applied to profits up to £50,000, with a marginal relief providing a gradual increase in the corporation tax rate for profits between £50,000 and £250,000.

11. Parent company profit for the year

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of comprehensive income in these financial statements. The profit after tax of the parent Company for the period/year was £-(2020 - £NIL).

G&L SCIENTIFIC HOLDINGS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

12. Tangible fixed assets

Group

	Leasehold property improvements £	Office equipment £	Computer equipment £	Total £
Cost or valuation				
At 1 January 2021	49,265	80,042	179,296	308,603
Additions	49,229	981	46,504	96,714
Acquisition of subsidiary	60,151	(180)	2,298	62,269
Exchange adjustments	52	262	943	1,257
At 31 December 2021	158,697	81,105	229,041	468,843
Depreciation				
At 1 January 2021	31,912	27,287	89,973	149,172
Charge for the period on owned assets	19,831	17,978	48,951	86,760
Transfers intra group	(12)	(65)	(225)	(302)
Exchange adjustments	28	147	483	658
At 31 December 2021	51,759	45,347	139,182	236,288
Net book value				
At 31 December 2021	106,938	35,758	89,859	232,555
At 31 December 2020	17,353	52,755	89,323	159,431

G&L SCIENTIFIC HOLDINGS LIMITED
--

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

13. Fixed asset investments

Company

	Investments in subsidiary companies £
Cost or valuation	
Additions	15,250,290
At 31 December 2021	15,250,290

Subsidiary undertakings

The following were subsidiary undertakings of the Company:

Name	Registered office	Class of shares	Holding
G&L Scientific Limited	The Old Barrel Store Brewery Courtyard, Draymans Lane, Marlow, United Kingdom, SL7 2FF	Ordinary	100%
G&L Scientific USA Inc	25 Independence Blvd, Warren, NJ 07059, United States	Ordinary	100%
G&L Scientific Canada Inc	Regus 711 Syntex Drive 3rd fl Mississauga ON Canada L5N 8C3	Ordinary	100%
G&L Scientific Switzerland	Stücki Village, Hochbergerstrasse 70, 4057 Basel, Switzerland	Ordinary	100%
G&L Scientific (Espana), S.L	Paseo de la Castellana, 93, 28046 Madrid, Spain	Ordinary	100%
G&L Scientific India Pvt Limited	Regus Spaces Mumbai Kanakia Wall Street 4th floor Andheri - Kurla Rd, Chakala, Andheri East Mumbai, Maharashtra 400093	Ordinary	100%

G&L SCIENTIFIC HOLDINGS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

13. Fixed asset investments (continued)**Subsidiary undertakings (continued)**

The aggregate of the share capital and reserves as at 31 December 2021 and the profit or loss for the period ended on that date for the subsidiary undertakings were as follows:

Name	Aggregate of share capital and reserves	Profit/(Loss)
	£	£
G&L Scientific Limited	(68,704)	57,803
G&L Scientific USA Inc	(221,420)	(104,091)
G&L Scientific Canada Inc	960,763	505,878
G&L Scientific Switzerland	(115,988)	(17,952)
G&L Scientific (Espana), S.L	(26,824)	(24,761)
G&L Scientific India Pvt Limited	150,624	50,875

G&L SCIENTIFIC HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021

14. Debtors

	Group 2021 £	Group 2020 £
Trade debtors	3,017,932	2,934,101
Other debtors	221,568	139,545
Prepayments and accrued income	192,130	225,916
Deferred taxation	2,586	1,054
	<u>3,434,216</u>	<u>3,300,616</u>

15. Cash and cash equivalents

	Group 2021 £	Group 2020 £
Cash at bank and in hand	705,999	869,048
	<u>705,999</u>	<u>869,048</u>

G&L SCIENTIFIC HOLDINGS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

16. Creditors: Amounts falling due within one year

	Group 2021 £	Group 2020 £
Bank loans	37,066	-
Trade creditors	471,450	348,121
Corporation tax	145,522	239,567
Other taxation and social security	227,528	276,053
Other creditors	844,439	502,829
Accruals and deferred income	1,320,518	1,447,854
	<u>3,046,523</u>	<u>2,814,424</u>

The following liabilities were secured:

	Group 2021 £	Group 2020 £
Other creditors	382,374	307,331
	<u>382,374</u>	<u>307,331</u>

Details of security provided:

Bibby Financial Services Ltd have a fixed and floating charge over G&L Scientific Ltd fixed assets

First Republic Bank has a charge over assets of G&L Scientific Inc

17. Creditors: Amounts falling due after more than one year

	Group 2021 £	Group 2020 £
Other loans	600,000	1,508,746
	<u>600,000</u>	<u>1,508,746</u>

G&L SCIENTIFIC HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2021

18. Share capital

	2021 £	2020 £
Allotted, called up and fully paid		
2,000,000 (2020 -) Ordinary shares shares of £0.01 each	20,000	-

The Company issued 2,000,000 ordinary shares with £0.01 per each share to exchange for all of the shares in G&L Scientific Limited and G&L Scientific Inc.

19. Reserves

Foreign exchange reserve

The foreign exchange reserve arises from the accumulation of non-distributable unrealised foreign exchange differences arising from the consolidation of foreign subsidiaries.

Merger Reserve

The merger reserve arises as a result of the group reconstruction which was enacted during the period.

Profit and loss account

The profit and loss account includes current year profits and losses.

20. Pension commitments

The Group operates a number of defined contributions pension schemes. The assets of the schemes are held separately from those of the Group in independently administered funds. The pension cost charge represents contributions payable by the Group to the funds and amounted to £365,517 (2020: 279,414). Contributions totalling £25,041 were payable to the fund at the balance sheet date and are included in creditors.

21. Commitments under operating leases

At 31 December 2021 the Group and the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

	Group 2021 £	Group 2020 £
Not later than 1 year	189,035	60,421
Later than 1 year and not later than 5 years	518,635	36,870
Later than 5 years	590,000	-
	<u>1,297,670</u>	<u>97,291</u>

G&L SCIENTIFIC HOLDINGS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021**

22. Group reconstruction

A group reconstruction was effected on 1 January 2021.
The entities which merged with the Company on that date were:
G&L Scientific Limited
G&L Scientific USA Inc.
G&L Scientific Canada Inc.
G&L Scientific (Espana), S.L.
G&L Scientific India Pvt Limited

The combination has been accounted for as a merger.
A merger reserve totalling £55,841 was recognised in merger reserves.

23. Related party transactions

In accordance with the exemption under Financial Reporting Standard No 102, the company does not disclose transactions with other wholly-owned companies within the G&L Scientific group.

At 31 December 2021, the company was owed £93,770 by and owed £13,013 to Blackrock Pharmaceuticals Ltd, a company in which P Griffin is a director and shareholder.

At 3 December 2021, the company owed £60,000 to Maidenhead United FC Ltd, a company in which P Griffin is a director.

At 31 December 2021, the company owed £1,014,451 to P Griffin, director. Interest is accrued on the outstanding loan balance